Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/ Refractory AML Using Antibody Radiation Conjugates (ARC)

Time: 11:45 am
day: Day One Discovery AM


  • Exploring Iomab-B, a CD45 I-131 ARC, enables bone marrow transplant in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
  • Outlining how responses in heavily pretreated patients for both Iomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutant disease, demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens
  • Revealing preclinical data to further show the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response